SCHEMBL677570

SCHEMBL677570

[C]1C=Cc2ccccc2S1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7685311 0.67
SCHEMBL207685 0.67 TRPA1 (0.31)
SCHEMBL7465889 0.67 KDM4E (0.33)
SCHEMBL4742301 0.66 TRPA1 (0.50)
SCHEMBL44493 0.63 MEN1 (0.30)
SCHEMBL28071912 0.63 MEN1 (0.30)
SCHEMBL29569587 0.63 MEN1 (0.30)
SCHEMBL3643757 0.63 MEN1 (0.30)
SCHEMBL22552069 0.63 TRPA1 (0.30)
Hydrogen Sulfide SCHEMBL27636981 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581476-B1 AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-16 EP claimed
US-20080096869-A1 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS LINDERS JOANNES T M 2008-04-24 US claimed
US-20060079506-A1 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICAL N.V. (BE) 2006-04-13 US claimed
EP-1581476-A2 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-10-05 EP claimed
WO-2004056745-A2 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-07-08 WO claimed
US-20030216414-A1 Method for preventing tissue injury from hypoxia CELL THERAPEUTICS,INC. 2003-11-20 US claimed
US-6638938-B1 By tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic CELL THERAPEUTICS, INC. 2003-10-28 US claimed
EP-0739203-A4 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS INC (US) 2000-12-20 EP claimed
US-5985926-A VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS CELL THERAPEUTICS, INC. (US) 1999-11-16 US claimed
US-5856331-A LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR CELL THERAPEUTICS, INC. (US) 1999-01-05 US claimed
WO-1998034601-A2 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1998-08-13 WO claimed
EP-0739203-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1996-10-30 EP claimed
EP-0728003-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1996-08-28 EP claimed
EP-0676958-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-10-18 EP claimed
WO-1995019171-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1995-07-20 WO claimed
WO-1995013075-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1995-05-18 WO claimed
WO-1995012396-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-05-11 WO claimed
US-4987130-A ANTIARRHYTHMIA AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-01-22 US claimed
EP-0200915-B1 AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM Roche Diagnostics GmbH (DE) 1989-09-27 EP claimed
WO-2022054927-A1 COMPOSITION FOR AUTOPHAGY ACTIVATION 国立大学法人大阪大学 2022-03-17 WO disclosed
EP-1581476-B1 AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-16 EP disclosed
US-20110275584-A1 PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS ONEPHARM RESEARCH AND DEVELOPMENT GMBH (AT) 2011-11-10 US disclosed
EP-1656349-B1 CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS LUNDBECK & CO AS H (DK) 2011-10-12 EP disclosed
US-7968601-B2 Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents JANSSEN PHARMACEUTICA N.V. (BE) 2011-06-28 US disclosed
US-7910613-B2 2-acylaminothiazole derivatives H. LUNDBECK A/S (DK) 2011-03-22 US disclosed
US-20110052625-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2011-03-03 US disclosed
US-7834008-B2 neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide H. LUNDBECK A/S (DK) 2010-11-16 US disclosed
US-20100087413-A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss ONEPHARM RESEARCH AND DEVELOPMENT GMBH (AT) 2010-04-08 US disclosed
US-20090269313-A1 ENCAPSULATION SYSTEM DIAKINE THERAPEUTICS, INC. (US) 2009-10-29 US disclosed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
WO-2009099582-A2 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2009-08-13 WO disclosed
US-20090137642-A1 2-Acylaminothiazole Derivatives H. LUNDBECK A/S (DK) 2009-05-28 US disclosed
EP-2036548-A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss onepharm Research & Development GmbH (AT) 2009-03-18 EP disclosed
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2008-12-04 US disclosed
US-7393827-B2 Pharmaceutical compositions and methods for restoring β-cell mass and function DIAKINE THERAPEUTICS, INC. (US) 2008-07-01 US disclosed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20080096869-A1 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS LINDERS JOANNES T M 2008-04-24 US disclosed
US-7332524-B2 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-19 US disclosed
WO-2008011518-A2 ENCAPSULATION SYSTEM DIAKINE THERAPEUTICS, INC. (US) 2008-01-24 WO disclosed
WO-2007146786-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING B-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2007-12-21 WO disclosed
EP-1841448-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION Diakine Therapeutics, Inc. (US) 2007-10-10 EP disclosed
US-7247630-B2 Uses of tricyclic compounds CELL THERAPEUTICS, INC. (US) 2007-07-24 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
US-20060281746-A1 Cyclopropyl derivatives as nk3 receptor antagonists H. LUNDBECK A/S (DK) 2006-12-14 US disclosed
US-7105543-B2 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2006-09-12 US disclosed
EP-1690864-A2 TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALLING CELL THERAPEUTICS, INC. (US) 2006-08-16 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060160736-A1 Pharmaceutical compositions and methods for restoring beta-cell mass and function DIAKINE THERAPEUTICS, INC. (US) 2006-07-20 US disclosed
WO-2006074051-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2006-07-13 WO disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
US-20060079506-A1 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICAL N.V. (BE) 2006-04-13 US disclosed
EP-1309586-B1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS LUNDBECK & CO AS H (DK) 2006-03-22 EP disclosed
WO-2005016884-A9 CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS LUNDBECK & CO AS H (DK) 2006-03-16 WO disclosed
US-20060004022-A1 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2006-01-05 US disclosed
EP-1171442-B1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS CELL THERAPEUTICS INC (US) 2005-12-07 EP disclosed
US-6958338-B2 4-,5-,6-and 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2005-10-25 US disclosed
EP-1581476-A2 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-10-05 EP disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed
US-6878715-B1 Therapeutic compounds for inhibiting interleukin-12 signals and method for using same CELL THERAPEUTICS, INC. (US) 2005-04-12 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
US-20050059685-A1 Pyridopyrimidine compounds and their uses CELL THERAPEUTICS, INC. (US) 2005-03-17 US disclosed
US-20050049262-A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same CELL THERAPEUTICS, INC. (US) 2005-03-03 US disclosed
US-6855713-B2 Benzimidazole derivatives, a process for their manufacture and use as a medicine BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20050032748-A1 Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease CELL THERAPEUTICS, INC. (US) 2005-02-10 US disclosed
EP-1165534-B1 BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2005-02-02 EP disclosed
US-6825180-B2 CYTOKINE INTRACELLULAR SIGNALING INHIBITORS; ANTIINFLAMMATORY AGENTS CELL THERAPEUTICS, INC. 2004-11-30 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
US-6774130-B2 TREATING CHRONIC INFLAMMATORY DISEASE, CHRONIC INTESTINAL INFLAMMATION, ARTHRITIS, PSORIASIS, ASTHMA AND AUTOIMMUNE DISORDERS; TH1 CELL-MEDIATED DISORDERS; FOR EXAMPLE, 1,2,3,6-TETRAHYDRO-7H-PURINE-2,6-DIONE DERIVATIVES CELL THERAPEUTICS, INC. 2004-08-10 US disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
WO-2004056745-A2 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-07-08 WO disclosed
US-6743809-B2 Indole Derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2004-06-01 US disclosed
EP-1305307-B1 INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS LUNDBECK & CO AS H (DK) 2004-05-06 EP disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20040023995-A1 Pyridopyrimidine compounds and their uses CELL THERAPEUTICS, INC. 2004-02-05 US disclosed
EP-1369414-A1 Enantiomerically pure Arylcycloalkyl hydroxycarboxylic esters, processes for their preparation and their use as modulators of muscarinic receptors Noe, Christian R. (AT) 2003-12-10 EP disclosed
US-6656956-B2 Tryptase inhibitor; antiinflamamtory agents, antiallergens BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-12-02 US disclosed
US-20030216414-A1 Method for preventing tissue injury from hypoxia CELL THERAPEUTICS,INC. 2003-11-20 US disclosed
US-6638938-B1 By tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic CELL THERAPEUTICS, INC. 2003-10-28 US disclosed
EP-1347976-A2 TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBIOTRS OF CYTOKINE SIGNALLING CELL THERAPEUTICS, INC. (US) 2003-10-01 EP disclosed
US-20030166665-A1 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2003-09-04 US disclosed
US-20030166664-A1 Indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2003-09-04 US disclosed
US-20030162801-A1 Tricyclic compounds and their uses GONG BAOQING (US) 2003-08-28 US disclosed
WO-2003070712-A1 THIOIBOTENIC ACID AND DERIVATIVES THEREOF H. LUNDBECK A/S (DK) 2003-08-28 WO disclosed
US-20030130265-A1 Benzimidazole derivatives, a process for their manufacture and use as a medicine BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-10 US disclosed
US-6586429-B2 For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders CELL THERAPEUTICS, INC. 2003-07-01 US disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed
US-20030105137-A1 Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-06-05 US disclosed
EP-1309586-A1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2003-05-14 EP disclosed
EP-1305307-A1 INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. Lundbeck A/S (DK) 2003-05-02 EP disclosed
EP-0937041-B1 Use of a pharmaceutically acceptable salt of (3R,2'R)-3-[(Cyclopently-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium for the preparation of a medicament NOE CHRISTIAN R (DE) 2003-04-23 EP disclosed
WO-2003024451-A1 2-(2-PHENYLETHYL)-BENZIMIDAZOLE-5-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-03-27 WO disclosed
EP-1288710-A1 Thermally developable infrared sensitive imaging materials containing heat-bleachable antihalation composition EASTMAN KODAK COMPANY (US) 2003-03-05 EP disclosed
US-6514677-B1 Thermally developable infrared sensitive imaging materials containing heat-bleachable antihalation composition EASTMAN KODAK COMPANY 2003-02-04 US disclosed
WO-2002094824-A1 PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USES CELL THERAPEUTICS, INC. (US) 2002-11-28 WO disclosed
WO-2002068421-A2 TRICYCLIC COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALING CELL THERAPEUTICS, INC. (US) 2002-09-06 WO disclosed
WO-2002062785-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS TRYPTASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-08-15 WO disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
US-20020103211-A1 TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES CELL THERAPEUTICS, INC. 2002-08-01 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed
US-20020028823-A1 THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME CELL THERAPEUTICS, INC. 2002-03-07 US disclosed
WO-2002016349-A1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2002-02-28 WO disclosed
WO-2002008223-A1 INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2002-01-31 WO disclosed
EP-1171442-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS CELL THERAPEUTICS, INC. (US) 2002-01-16 EP disclosed
EP-1165534-A2 BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS Boehringer Ingelheim Pharma KG (DE) 2002-01-02 EP disclosed
US-6323207-B1 TREATMENT OR REDUCTION OF TISSUE DAMAGE DUE TO ISCHAEMIA WHICH COMPRISES ADMINISTERING TO A HOST SUFFERING FROM ISCHAEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-11-27 US disclosed
EP-0739203-A4 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS INC (US) 2000-12-20 EP disclosed
WO-2000061583-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 2000-10-19 WO disclosed
US-6127423-A USED IN DISEASES IN WHICH THE LTB4-RECEPTOR-ANTAGONISTIC PROPERTIES PLAY A PART, INCLUDING ARTHRITIS, ASTHMA, CHRONIC OBSTRUCTIVE LUNG DISEASES, E.G., CHRONIC BRONCHITIS, PSORIASIS, ULCERATIVE COLITIS, GASTRO- OR ENTEROPATHY BOEHRINGER INGELHEIM KG (DE) 2000-10-03 US disclosed
US-6114335-A Benzoylguanidine derivatives, process for their preparation their use in the preparation of medicines BOEHRINGER INGELHEIM KG (DE) 2000-09-05 US disclosed
EP-1015421-A1 NEW PHENYLAMIDINE DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim Pharma KG (DE) 2000-07-05 EP disclosed
WO-2000017176-A2 BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-03-30 WO disclosed
US-5985926-A VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS CELL THERAPEUTICS, INC. (US) 1999-11-16 US disclosed
EP-0937041-A1 PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS Noe, Christian R. (DE) 1999-08-25 EP disclosed
US-5856331-A LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR CELL THERAPEUTICS, INC. (US) 1999-01-05 US disclosed
EP-0882031-A1 NOVEL BENZOYL GUANIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF MEDICINES Boehringer Ingelheim Pharma KG (DE) 1998-12-09 EP disclosed
US-5824677-A SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE CELL THERAPEUTICS, INC. (US) 1998-10-20 US disclosed
WO-1998034601-A2 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1998-08-13 WO disclosed
US-5777117-A ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE, CYTOTOXIC AGENTS; MICROBIOCIDES, FUNGICIDES CELL THERAPEUTICS, INC. (US) 1998-07-07 US disclosed
WO-1998021183-A1 PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS NOE CHRISTIAN R (AT) 1998-05-22 WO disclosed
US-5750575-A ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS; CYTOTOXIC AGENTS; MICROBIOCIDES; FUNGICIDES CELL THERAPEUTICS, INC. (US) 1998-05-12 US disclosed
US-5670507-A Method for reversing multiple drug resistant phenotype CELL THERAPEUTICS, INC. (US) 1997-09-23 US disclosed
WO-1997026253-A1 NOVEL BENZOYL GUANIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF MEDICINES BOEHRINGER INGELHEIM PHARMA KG (DE) 1997-07-24 WO disclosed
US-5641783-A ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS CELL THERAPEUTICS, INC. (US) 1997-06-24 US disclosed
WO-1997021670-A1 NEW PHENYLAMIDINE DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM KG (DE) 1997-06-19 WO disclosed
EP-0739203-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1996-10-30 EP disclosed
EP-0728003-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1996-08-28 EP disclosed
EP-0676958-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-10-18 EP disclosed
WO-1995019171-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1995-07-20 WO disclosed
WO-1995013808-A1 METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION CELL THERAPEUTICS, INC. (US) 1995-05-26 WO disclosed
WO-1995013075-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1995-05-18 WO disclosed
WO-1995012396-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-05-11 WO disclosed
US-5254595-A Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1993-10-19 US disclosed
EP-0278621-B1 SUBSTITUTED AMINE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1991-06-12 EP disclosed
US-4987130-A ANTIARRHYTHMIA AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-01-22 US disclosed
US-4863949-A CARDIOVASCULAR DISORDER TREATMENT BOEHRINGER MANNHEIM GMBH (DE) 1989-09-05 US disclosed
EP-0278621-A1 Substituted amine derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1988-08-17 EP disclosed
EP-0278621-A1 Substituted amine derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1988-08-17 EP disclosed